Class Action Signal

Class Action Signal

Class ActionsNews
Class ActionsNewsAboutContact
Public case information

GeneDx Securities Class Action

Follow to receive email when new source reporting is added to this case. Email delivery also depends on your profile notification settings and a verified email address.

GeneDx Holdings · GeneDx securities · New Filing

Last updated

About this case

A securities class action was filed against GeneDx Holdings Corp. and certain executive officers on behalf of purchasers of GeneDx common stock between April 16, 2025, and May 4, 2026. The complaint alleges violations of the Securities Exchange Act of 1934; the matter was filed in June 2026, and its current procedural stage beyond the lead-plaintiff deadline is not specified.

Case overview

Defendant company
GeneDx Holdings
Product or service
GeneDx securities
Case name
Basma v. GeneDx Holdings Corp., et al.
Court case number
3:26-cv-00880
Case status
New Filing
Lawsuit type
Securities
Reported harm
Misrepresentation

Important dates

Lead Plaintiff Application
Class Action Information and Case Intake
Lead Plaintiff and Investor Contact

Participation information

Availability is based on each listed participation option and its deadline.

Lead Plaintiff Application

Purchasers of GeneDx stock during the period from April 16, 2025, through May 4, 2026, who suffered substantial losses and wish to serve as lead plaintiff.

Contact Barrack Rodos & Bacine by calling 877-386-3304 or emailing investoralert@barrack.com.

Type
Lead Plaintiff
Status
Deadline passed
Reported proof requirement
Unclear
Apply as lead plaintiff

Class Action Information and Case Intake

The law firm provides information for investors who purchased GeneDx Holdings common stock during the stated class period.

Review the case information and contact the law firm through the listed intake page.

Type
Law Firm Signup
Status
Deadline passed
Reported proof requirement
Unclear
Contact law firm Contact law firm

Lead Plaintiff and Investor Contact

Investors who purchased GeneDx securities between April 16, 2025 and May 4, 2026, inclusive, are invited to contact the Schall Law Firm regarding the lawsuit.

Contact Brian Schall or the Schall Law Firm to discuss rights and potential participation.

Type
Law Firm Signup
Status
Deadline passed
Reported proof requirement
Unclear

Holzer & Holzer investor inquiry

The promotional communication invites people who purchased GeneDx shares between April 16, 2025 and May 4, 2026 and experienced an investment loss to discuss their legal rights with Holzer & Holzer.

Contact Marshall P. Dees, Esq. by email or telephone, or use the firm's online case page for more information.

Type
Law Firm Signup
Status
Unknown

Bragar Eagel & Squire Legal Rights Inquiry

People who purchased or acquired WGS common stock between April 16, 2025, and May 4, 2026, may contact Bragar Eagel & Squire to discuss their legal rights.

Contact Bragar Eagel & Squire at (212) 355-4648 to discuss legal rights.

Type
Law Firm Signup
Status
Unknown
Reported proof requirement
Unclear

GeneDx investor representation inquiry

The announcement invites GeneDx investors to contact Bronstein, Gewirtz & Grossman regarding representation in the securities class action.

Contact Bronstein, Gewirtz & Grossman at 917-590-0911 or [email protected].

Type
Law Firm Signup
Status
Unknown

Pomerantz investor inquiry

Investors with losses on investments in GeneDx are invited to contact Pomerantz LLP regarding the action.

Contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, or 888-4-POMLAW, extension 7980. Email inquiries are encouraged to include a mailing address, telephone number, and number of shares purchased.

Type
Law Firm Signup
Status
Unknown
Reported proof requirement
Unclear
Business Wire source

This information does not determine whether you qualify for a case.

Sources

Public reporting associated with this case.